Skip to main content
. 2023 Aug 21;129(8):1274–1283. doi: 10.1038/s41416-023-02403-x

Fig. 4. Survival outcome according to primary HER2-low expression.

Fig. 4

RFI and OS according to primary HER2-low expression of (a, d) all, (b, e) ER-positive, and (C, F) ER-negative, HER2-negative patients. RFI recurrence free interval, OS overall survival, HER2 human epidermal growth factor receptor-2, ER estrogen receptor.